Healthcare / BiotechnologyNYSE
$10.30
-1.13 (-9.84%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $-586.5M · quality 37.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
11/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.6B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-1418.8%
↓Gross Margin
N/A
•Debt/Equity
5.47
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.83x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-738.8M · FCF $-610.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Net Income | $-738.8M | $-738.8M | $-846.4M | $-408.2M | $-570.3M | $-213.8M | $-118.7M |
| EBITDA | $-735.5M | $-735.5M | $-877.3M | $-429.1M | $-566.5M | $-217.5M | $-114.4M |
| EPS | — | — | -9.28 | -5.73 | -12.75 | -5.43 | -3.01 |
| Balance Sheet | |||||||
| Debt/Equity | 5.47 | 5.47 | 0.09 | 0.07 | 0.06 | — | — |
| Current Ratio | 7.41 | 7.41 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-610.2M | $-610.2M | $-586.5M | $-334.8M | $-338.8M | $-146.8M | $-77.1M |
| Returns | |||||||
| ROE | -1418.8% | -1418.8% | -199.9% | -95.4% | -105.8% | -616.3% | -707.2% |
| Valuation | |||||||
| P/B | 26.28 | 26.28 | 8.33 | 7.09 | 1.20 | — | — |
| Growth & Yield | |||||||
| EPS Growth | — | — | -62.0% | 55.1% | — | -80.4% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-34.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-9.28 → n/d
Residual
-34.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.